Requirements for the construction of antibody heterodimers for the direction of lysis of tumors by human T cells.

C F Scott; W A Blättler; J M Lambert; R S Kalish; C Morimoto; S F Schlossman

doi:10.1172/JCI113473

Dana-Farber Cancer Institute, Boston, Massachusetts 02115.

Find articles by Scott, C. in: PubMed | Google Scholar

Dana-Farber Cancer Institute, Boston, Massachusetts 02115.

Find articles by Blättler, W. in: PubMed | Google Scholar

Dana-Farber Cancer Institute, Boston, Massachusetts 02115.

Find articles by Lambert, J. in: PubMed | Google Scholar

Dana-Farber Cancer Institute, Boston, Massachusetts 02115.

Find articles by Kalish, R. in: PubMed | Google Scholar

Dana-Farber Cancer Institute, Boston, Massachusetts 02115.

Find articles by Morimoto, C. in: PubMed | Google Scholar

Dana-Farber Cancer Institute, Boston, Massachusetts 02115.

Find articles by Schlossman, S. in: PubMed | Google Scholar

Published in Volume 81, Issue 5 on May 1, 1988
J Clin Invest. 1988;81(5):1427–1433. https://doi.org/10.1172/JCI113473.
© 1988 The American Society for Clinical Investigation

Published May 1, 1988 - Version history

We constructed a series of MAb heterodimers consisting of the J5 (anti-common acute lymphoblastic leukemia antigen [CALLA]) antibody and antibodies to a variety of structures present on the surface of activated human T cells, including CD3 antigen (T cell receptor-associated glycoproteins), CD2 antigen (T11/E-rosette receptor), CD25 antigen (IL-2 receptor), and the transferrin receptor. We tested the ability of these heterodimers to direct a CD2 + CD3 + CD8 + CD4 - CD25 + transferrin receptor + MHC-restricted human cytolytic T lymphocyte (CTL) clone to lyse a CALLA + human tumor in vitro. Only heterodimers containing an anti-CD3 antibody or activating antibodies to CD2 could direct the clone to lyse these human tumor targets, even when the clone was additionally activated with anti-CD3 or anti-CD2 antibodies. Our findings may have implications in the design of strategies for the use of such reagents in the treatment of human neoplasia.

Images.

Version 1 (May 1, 1988): No description

Requirements for the construction of antibody heterodimers for the direction of lysis of tumors by human T cells.

C F Scott Jr, W A Blättler, J M Lambert, R S Kalish, C Morimoto, and S F Schlossman

Article tools

Metrics

Go to

Requirements for the construction of antibody heterodimers for the direction of lysis of tumors by human T cells.

C F Scott Jr, W A Blättler, J M Lambert, R S Kalish, C Morimoto, and S F Schlossman

Article tools

Metrics

Go to

Sign up for email alerts